About Respicardia
Respicardia is a Healthcare company based in Minnetonka (United States) founded in 2006, and was acquired by ZOLL AEDs in April 2021. It operates as a manufacturing implantable stimulation device to improve cardiovascular health by restoring natural breathing at night. Respicardia has raised $184.62 million across 11 funding rounds from investors including Ares Capital Corporation, ZOLL AEDs and Sorin Group. Respicardia offers products and services including remedē System, remedē EL System, and remedē EL-X System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is RESPICARDIA INC. Its competitors include CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
Respicardia was founded in 2006 and is headquartered in Minnetonka, United States. Operations focus on the medical device sector, where implantable therapies are created to address central sleep apnea in heart failure patients. The remedē System is offered, consisting of a neurostimulation device, sensing and stimulation wires, and a portable programmer tablet. This system aims to normalize breathing during sleep, potentially alleviating symptoms like fatigue and improving cardiovascular outcomes.
- Total Equity Funding$184.62M (USD)
in 11 rounds
- Latest Funding Round$58.5M (USD), Series D
Dec 2017
- InvestorsAres Capital Corporation
& 8 more
- Acquired byZOLL AEDs
(Apr 2021)
Products & Services of Respicardia
Respicardia offers a comprehensive portfolio of products and services, including remedē System, remedē EL System, and remedē EL-X System.
Implantable stimulator for treating central sleep apnea in adults.
Advanced implantable option for central sleep apnea management.
FDA-approved system for moderate to severe sleep apnea therapy.
Apps and channels of Respicardia
its YouTube channel zollmedical has 49.6K subscribers and 30 videos.
Videos from Respicardia
The most watched videos on Respicardia's YouTube channel, zollmedical (49.6K subscribers). Click a video to play it here.
More on zollmedical.
Funding Insights of Respicardia
Respicardia has successfully raised a total of $184.62M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $58.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $184.62M
- Total Rounds 11
- Last Round Series D — $58.5M
- First Round $5.5M
(Dec 2006)
- Investors Count 9
Latest 10 of 11 funding rounds of Respicardia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $58.5M | Series D | – | ZOLL AEDs | – |
| Jun 2017 | $5.12M | Series C | – | – | – |
| Oct 2014 | $25.09M | Series C | – | Sorin Group | – |
| Aug 2014 | $5M | Series C | – | – | – |
| Sep 2013 | $10M | Series C | – | – | – |
| Aug 2013 | $27.21M | Series C | – | – | – |
| Sep 2012 | $6M | Debt – Conventional | – | – | |
| Aug 2012 | $6M | Debt – Conventional | – | – | |
| Aug 2010 | $27.21M | Series C | – | – | – |
| Oct 2008 | $21M | Series B | – | Polaris Partners, Versant Ventures |
9 investors in total: 9 institutional.
Investors in Respicardia
Respicardia has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Ares Capital Corporation, ZOLL AEDs and Sorin Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and debt investments are managed for businesses. | 2004 | arescapitalcorp.com | Los Angeles, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Early-stage US healthcare investments are made by Accuitive Medical Ventures. | – | amvpartners.com | Duluth, United States | |
- | – | affinitycapital.net | - | |
Life science & tech focused VC firm investing in companies in the US | – | threearchpartners.com | San Mateo, United States | |
Medical devices and software for emergency care are developed. | 1983 | zoll.com | Chelmsford, United States | |
Medical devices for cardiac surgery and rhythm management are developed. | 1956 | sorin.com | Milan, Italy | |
Provides advertising, branding, graphic design, and digital experiences. | 2014 | rkventure.com | Albuquerque, United States |
Investor details for Respicardia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Respicardia
40 people are tracked at Respicardia (11 in leadership, 29 in team).
| Name | Role | Group |
|---|---|---|
Robin Germany | Chief Medical Officer | Leadership |
Kathy McPherson | Director, Clinical Affairs | Leadership |
Collin Anderson | President | Leadership |
Andy Wolle | Senior Director Of Finance | Leadership |
Stephanie Davy | Director of Human Resources | Leadership |
Kevin Bentley | VP, Quality Assurance & Regulatory Affairs | Leadership |
Todd Goblish | VP of Research & Development, & Operations | Leadership |
Jessica Demarte | Director Quality And Regulatory Affairs | Leadership |
Lou Runez | Area Sales Director - Western Region | Leadership |
Jason Vinson | VP, Sales | Leadership |
Anthony Locatelli | Marketing Director | Leadership |
Shawn O. | Technical Sleep Specialist | Team |
Heather Clary | Clinical Project Manager | Team |
Stan Rieder | R&d Technician | Team |
Ana Guarino | Territory Manager | Team |
Punam Patel Ms | Senior Field Clinical Specialist | Team |
Frank Piskolich | General Counsel | Team |
Kim Gunlock | Territory Manager | Team |
Krista Sauerer | Human Resources Manager | Team |
Abby Vanharen | Senior Quality And Regulatory Specialist | Team |
20 more people are available in the full profile.
Complete people profiles for Respicardia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Respicardia
4 dated milestones of Respicardia across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Respicardia is founded.
- Funding First funding round of $5.5M.
- Funding Latest funding round, Series D, of $58.5M.
- Exit Acquired by ZOLL AEDs.
Competitors of Respicardia
Respicardia has 10 listed competitors in our database, 10 of them funded. They include CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cvrx.com | 2001 | Minneapolis, United States | $368.5M | 142 | Implantable technology for hypertension and heart failure is developed. | |
| sequanamedical.com | 2006 | Zurich, Switzerland | $35.5M | – | Implantable battery-powered pumps for ascites removal are developed. | |
| adonamed.com | 2017 | Campbell, United States | $71M | – | Medical devices for heart failure management are developed. | |
| elementscience.com | 2013 | San Francisco, United States | $192.6M | – | Wearable patch defibrillators are developed for sudden cardiac arrest treatment. | |
| vwavemedical.com | 2009 | Caesarea, Israel | $128M | – | Implantable inter-atrial shunts are developed to treat chronic heart failure. | |
| ancoraheart.com | 2001 | San Francisco, United States | $151.26M | 89 | Minimally invasive ventriculoplasty system for heart failure and FMR | |
| bioventrix.com | 2003 | San Ramon, United States | $181.42M | 20 | Ventricular reconstruction devices for heart failure are developed. | |
| syncardia.com | 2001 | Tucson, United States | $60.96M | – | Total artificial hearts are developed for cardiac replacement therapy. | |
| heartware.com | 2005 | Framingham, United States | $12.38M | 547 | Miniaturized ventricular assist devices are developed for heart failure treatment. | |
| reprievecardio.com | 2018 | Milford, United States | $119.37M | – | Medical device for acute heart failure treatment is developed. |
Detailed competitors of Respicardia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Respicardia (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Respicardia
Complete news archive for Respicardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Respicardia
Respicardia was founded in 2006.
Respicardia is headquartered in Minnetonka, United States. It is registered at Minnetonka, Minnesota, United States.
Respicardia is a funded company, having raised a total of $184.62M across 11 funding rounds to date. The company's 1st funding round was a Series B of $21M, raised on Dec 2006.
Respicardia was founded in 2006 and is headquartered in Minnetonka, United States. Operations focus on the medical device sector, where implantable therapies are created to address central sleep apnea in heart failure patients. The remedē System is offered, consisting of a neurostimulation device, sensing and stimulation wires, and a portable programmer tablet. This system aims to normalize breathing during sleep, potentially alleviating symptoms like fatigue and improving cardiovascular outcomes.
Respicardia's top competitors include Sequana Medical, CVRx and Adona Medical.
Respicardia offers remedē System, remedē EL System, and remedē EL-X System.
Respicardia has 9 investors. Key investors include Ares Capital Corporation, ZOLL AEDs, Sorin Group, Polaris Partners, and Versant Ventures.
Respicardia operates through Respicardia Inc.
Yes. Respicardia was acquired by ZOLL AEDs in April 2021.